Translational Research
Volume 156, Issue 5 , Pages 273-281, November 2010

Dobutamine-norepinephrine, but not vasopressin, restores the ventriculoarterial matching in experimental cardiogenic shock

  • Ole-Jakob How

      Affiliations

    • Laboratory of Surgical Research, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
    • Corresponding Author InformationReprint requests: Ole-Jakob How, Laboratory of Surgical Research, Institute of Clinical Medicine, University of Tromsø, N-9037 Tromsø, Norway
  • ,
  • Assami Røsner

      Affiliations

    • Laboratory of Surgical Research, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
  • ,
  • Anders B. Kildal

      Affiliations

    • Laboratory of Surgical Research, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
  • ,
  • Thor A. Stenberg

      Affiliations

    • Laboratory of Surgical Research, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
  • ,
  • Petter F. Gjessing

      Affiliations

    • Laboratory of Surgical Research, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
  • ,
  • Stig E. Hermansen

      Affiliations

    • Laboratory of Surgical Research, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
    • Department of Cardiothoracic and Vascular Surgery, University Hospital North Norway, Tromsø, Norway
  • ,
  • Truls Myrmel

      Affiliations

    • Laboratory of Surgical Research, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
    • Department of Cardiothoracic and Vascular Surgery, University Hospital North Norway, Tromsø, Norway

Received 15 April 2010; received in revised form 19 July 2010; accepted 21 July 2010. published online 23 August 2010.

We assessed the hemodynamic effects of guideline therapy in experimental cardiogenic shock and compared this treatment with a combination containing an alternative vasopressor (arginine vasopressin, AVP). Our hypothesis was that combined dobutamine-norepinephrine still is the superior inopressor therapy assessed by ventriculoarterial matching in both systole and diastole. Cardiogenic shock (CS) was induced by coronary microembolization in 16 pigs. Dobutamine (Dobu, 2ug/kg/min) alone and combined with either norepinephrine (NE, 100 ng/kg/min) or the pure vasopressor AVP (0.001 u/kg/min) were infused. In CS, Dobu increased cardiac output (CO) and central venous oxygen saturation (SVO2) from 74 ± 3 mL/kg and 37 ± 2% to 103 ± 8 mL/kg and 49 ± 3%. Adding NE resulted in a further improvement of CO (125 ± 9 mL/kg) and SVO2 (59 ± 4%) because of an increased heart rate and contractility with minimal change in systemic vascular resistance. Also, energy transfer from the ventricle to the arterial system was restored partly by Dobu and was normalized by supplementing NE. In contrast, supplemental AVP further worsened the shock state by decreasing CO (70 ± 6 mL/kg) and SVO2 (45 ± 5%) compared with Dobu alone. Combined Dobu-NE has an efficient hemodynamic profile in CS. A pure afterload increasing substance used in acute ischemic CS aggravates the shock state by causing a ventriculoarterial mismatch despite its use in combination with an inotropic compound.

Abbreviations: AVP, arginine vasopressin, CO, cardiac output, CS, cardiogenic shock, CVP, central venous pressure, Dobu, dobutamine, dP/dt, derivative of ventricular pressure, EDV, end diastolic volume, EDPVR, end diastolic pressure volume relationship, EES, end systolic elastance, EF, ejection fraction, ESPVR, end systolic pressure volume relationship, ESV, end systolic volume, MAP, mean arterial pressure, MPAP, mean pulmonary artery pressure, NE, norepinephrine, PCWP, pulmonary capillary wedge pressure, PRSW, preload recruitable stroke work, PV, pressure-volume, SD, standard deviation, SV, stroke volume, SVO2, central venous oxygen saturation, SVR, systemic vascular resistance, SW, stroke work, Tau, time constant of isovolumetric relaxation, V0, x-axis intercept of the ESPVR, VCO, vena cava occlusion

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the health authorities of north Norway (“Helse Nord”).

PII: S1931-5244(10)00159-3

doi:10.1016/j.trsl.2010.07.011

Translational Research
Volume 156, Issue 5 , Pages 273-281, November 2010